Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Capecitabine × 90 days × Clear all

Sponsor

Conditions

Breast Neoplasms 36 Stomach Neoplasms 17 Rectal Neoplasms 14 Colorectal Neoplasms 13 Triple Negative Breast Neoplasms 10 Neoplasm Metastasis 10 Adenocarcinoma Of Esophagus 7 Esophageal Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Nasopharyngeal Carcinoma 5 Colonic Neoplasms 5 Adenocarcinoma 5 Recurrence 4 Neoplasms 4 Cholangiocarcinoma 4 Locally Advanced Rectal Cancer 3 Colorectal Cancer Metastatic 3 Brain Neoplasms 3 Anus Neoplasms 3 Somatostatinoma 2 Pathologic Complete Response 2 HER2-positive Gastric Cancer 2 Gallbladder Neoplasms 2 Biliary Tract Neoplasms 2 Bile Duct Neoplasms 2 Advanced Solid Tumour 2 Solid Cancer 1 Resectable Colon Cancer 1 Rectal Neoplasms Malignant 1 Pancreatic Neoplasms 1

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡